Icon

Olux E - (0.05% Aerosol, Foam; Topical)

Clobetasol Propionate Delcor Pharma
0.05% Aerosol, Foam; Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
Olux-E (clobetasol propionate foam) Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older
Yes
******* *** *** ***** ** **** **** ** **** ******* *******- **** *, **** & *******-**** *, **** *** *** ************ *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** *******, ********* ** *** ***** ** ***** ******* ******** *** ******* ** *** ****. ******* **** **** ***** **** ** ** *** **** ******* *** *** ************ *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** **** ** **** ***** *** ***** ** ********** *** *** ***** *** ** ****** **** *** ****** ******* **** ********. **** **** ** * *** *********** *********** *** ******* *** **** **** **** *, ****.
Olux E Patent 1 Patent 2 Patent 3 Patent 4
******* ******* ******* ******* *******
*** (****) ******* ******* ******* *******
******** ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** **** ******* ******** ******** ** *** ****
*** (****) ** \ ** *** *, **** ******* ******** *** ****** *******
******** ** \ ** *** **, **** ******* ******** ******** ** **** **, ****
  1. ****, **** : ******* ******** ******* ***** *** **** ** **** *.**% **** **** *** ****** ******* , *******.
  2. ****, **** : ******* ***** **** ******* ******* ** ******** ***** ** ********.
  3. *** *, **** : ********** *** ********* **** ******* ***** *** ***** ** ********* *** *** *****.
  4. *** *, **** : ******* ******** **** *.
  5. *** **, **** : **** ******** ****** ***** *** **** ** **** ******* '*** & '*** **** ******** ** **** *, ****.
  6. *** *, **** : ****** ***** * ********** ******* **** ** ******** ***** ** ********.
  7. *** **, **** : ********** *** ********* **** *** (****) ***** *** ***** ** ********* *** *** *****.
  8. *** **, **** : ****** ***** * **** ******* ******** **** ****** ******* (**** *, ****).
  9. *** **, **** : ********** ********* **** ******** *** ***** ** *** ********* *** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.